{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Test+Product+1&page=2",
    "query": {
      "intervention": "Test Product 1",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Test+Product+1&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-26T11:34:28.604Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06267274",
      "title": "A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Open-angle Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "Bimatoprost Ophthalmic Solution, 0.01%",
          "type": "DRUG"
        },
        {
          "name": "LUMIGAN® (bimatoprost ophthalmic solution) 0.01%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amneal Pharmaceuticals, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 240,
      "start_date": "2024-04-01",
      "completion_date": "2025-05-01",
      "has_results": false,
      "last_update_posted_date": "2024-08-06",
      "last_synced_at": "2026-09-26T11:34:28.604Z",
      "location_count": 4,
      "location_summary": "Bakersfield, California • Newport Beach, California • Morrow, Georgia + 1 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Morrow",
          "state": "Georgia"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06267274"
    },
    {
      "nct_id": "NCT04439110",
      "title": "Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Lymphoma",
        "Advanced Malignant Solid Neoplasm",
        "Hematopoietic and Lymphoid Cell Neoplasm",
        "Refractory Lymphoma",
        "Refractory Malignant Solid Neoplasm",
        "Refractory Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Trastuzumab Emtansine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 38,
      "start_date": "2015-08-12",
      "completion_date": "2027-03-31",
      "has_results": true,
      "last_update_posted_date": "2026-05-08",
      "last_synced_at": "2026-09-26T11:34:28.604Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04439110"
    },
    {
      "nct_id": "NCT03471182",
      "title": "Investigation of Cocaine Addiction Using mGluR5 PET and fMRI",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cocaine Dependence"
      ],
      "interventions": [
        {
          "name": "Psychiatric and Cognitive Testing",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Cocaine Self-adminstration",
          "type": "DRUG"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "RADIATION"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "DRUG",
        "RADIATION",
        "OTHER"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 32,
      "start_date": "2018-02-26",
      "completion_date": "2022-08-18",
      "has_results": true,
      "last_update_posted_date": "2024-02-29",
      "last_synced_at": "2026-09-26T11:34:28.604Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03471182"
    },
    {
      "nct_id": "NCT02978508",
      "title": "Bio-equivalence Study Comparing Permethrin Cream, 5% With Elimite in Patients With Active Scabies.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Scabies"
      ],
      "interventions": [
        {
          "name": "Permethrin Cream, 5%",
          "type": "DRUG"
        },
        {
          "name": "Elimite",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayne Pharma International Pty Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 140,
      "start_date": "2016-11",
      "completion_date": "2017-05",
      "has_results": true,
      "last_update_posted_date": "2020-09-02",
      "last_synced_at": "2026-09-26T11:34:28.604Z",
      "location_count": 3,
      "location_summary": "Miami, Florida • Richland, Washington",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Richland",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02978508"
    },
    {
      "nct_id": "NCT04545385",
      "title": "A Study to Test if TEV-48574 is Effective in Relieving Asthma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "TEV-48574",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 65,
      "start_date": "2020-10-07",
      "completion_date": "2022-01-17",
      "has_results": true,
      "last_update_posted_date": "2023-03-13",
      "last_synced_at": "2026-09-26T11:34:28.604Z",
      "location_count": 55,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Bakersfield, California + 47 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04545385"
    },
    {
      "nct_id": "NCT00483496",
      "title": "Evaluation of the Protection Activity of Microfine Titanium Dioxide (Ti02), Pigmentary Ti02 and Bisoctrizole and Their Combinations in Voluntary Patients With Idiopathic Solar Urticaria (SU)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Idiopathic Solar Urticaria"
      ],
      "interventions": [
        {
          "name": "Titanium dioxide (Ti02) microfine 12.15% alone (formula RV3131A-MV1209)",
          "type": "DRUG"
        },
        {
          "name": "Ti02 pigmentary 3% alone (formula RV3131A-MV1211)",
          "type": "DRUG"
        },
        {
          "name": "bisoctrizole 10% alone (formula RV3131A-MV1237)",
          "type": "DRUG"
        },
        {
          "name": "Ti02 microfine 12.15% + Ti02 pigmentary 3% (formula RV3131A-MV1213)",
          "type": "DRUG"
        },
        {
          "name": "Ti02 microfine 12.15% + bisoctrizole 10% (formula RV3131A-MV1329)",
          "type": "DRUG"
        },
        {
          "name": "Ti02 pigmentary 3% + bisoctrizole 10% (formula RV3131A-MV1212)",
          "type": "DRUG"
        },
        {
          "name": "Ti02 microfine 12.15% + Ti02 pigmentary 3% + bisoctrizole 10% [V0096 CR (formula RV3131A-MV1166)]",
          "type": "DRUG"
        },
        {
          "name": "V0096 CR vehicle (formula RV3131A-MV1197)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Orfagen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2007-09",
      "completion_date": "2008-04",
      "has_results": true,
      "last_update_posted_date": "2017-12-22",
      "last_synced_at": "2026-09-26T11:34:28.604Z",
      "location_count": 2,
      "location_summary": "Detroit, Michigan • New York, New York",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00483496"
    },
    {
      "nct_id": "NCT04302025",
      "title": "A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Alectinib",
          "type": "DRUG"
        },
        {
          "name": "Entrectinib",
          "type": "DRUG"
        },
        {
          "name": "Vemurafenib",
          "type": "DRUG"
        },
        {
          "name": "Cobimetinib",
          "type": "DRUG"
        },
        {
          "name": "Pralsetinib",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "SBRT",
          "type": "DRUG"
        },
        {
          "name": "Resection",
          "type": "PROCEDURE"
        },
        {
          "name": "Chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "Divarasib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 99,
      "start_date": "2020-11-06",
      "completion_date": "2030-05-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-10",
      "last_synced_at": "2026-09-26T11:34:28.604Z",
      "location_count": 38,
      "location_summary": "Duarte, California • Irvine, California • Los Angeles, California + 28 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04302025"
    },
    {
      "nct_id": "NCT05833217",
      "title": "Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Long COVID",
        "Insulin Resistance",
        "Insulin Sensitivity"
      ],
      "interventions": [
        {
          "name": "Adipose Tissue Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Steady State Plasma Glucose (SSPG) Test",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 55,
      "start_date": "2023-06-06",
      "completion_date": "2025-12-31",
      "has_results": false,
      "last_update_posted_date": "2024-12-04",
      "last_synced_at": "2026-09-26T11:34:28.604Z",
      "location_count": 2,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05833217"
    },
    {
      "nct_id": "NCT01769677",
      "title": "A Crossover Study to Assess the Bioequivalence of Hydrocodone Bitartrate Extended-Release Tablet",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pain"
      ],
      "interventions": [
        {
          "name": "90 mg dose of the hydrocodone bitartrate extended-release tablet administered as either two 45-mg tablets (Treatment A) or one 90-mg tablet (Treatment B).",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 54,
      "start_date": "2013-01",
      "completion_date": "2013-02",
      "has_results": false,
      "last_update_posted_date": "2013-03-20",
      "last_synced_at": "2026-09-26T11:34:28.604Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01769677"
    },
    {
      "nct_id": "NCT04214067",
      "title": "Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Endometrial Endometrioid Adenocarcinoma",
        "Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8",
        "Stage II Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Brachytherapy",
          "type": "RADIATION"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "External Beam Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "X-Ray Imaging",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "RADIATION",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 164,
      "start_date": "2020-04-09",
      "completion_date": "2027-02-05",
      "has_results": false,
      "last_update_posted_date": "2026-07-02",
      "last_synced_at": "2026-09-26T11:34:28.604Z",
      "location_count": 275,
      "location_summary": "Birmingham, Alabama • Clovis, California • Concord, California + 195 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Clovis",
          "state": "California"
        },
        {
          "city": "Clovis",
          "state": "California"
        },
        {
          "city": "Concord",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04214067"
    }
  ]
}